Cure8 research brief
If validated, epithelial CXCL1 could become a tissue biomarker that helps track remission specifically in ulcerative colitis and serve as a functional readout for epithelial-directed therapies tested in patient-derived organoids.
Researchers studying IBD biomarkers, clinicians and translational scientists working on ulcerative colitis, and teams developing organoid-based therapeutic screening platforms.
The study analyzed bulk and single-cell transcriptomic data from IBD clinical-trial cohorts (including anti-TNFα and anti-integrin therapies) and compared chemokine expression with clinical remission status. CXCL1 showed the strongest and most consistent correlation with Mayo scores and was enriched in enterocytes and LGR5+ stem cells in UC.
CXCL1 levels normalized in patients in remission and stayed elevated in non-responders. The same pattern was not observed for Crohn’s disease. How researchers might use this: CXCL1 could be tested as a tissue-based biomarker in future prospective studies and considered as a functional readout in patient-derived colonic organoid screening for UC therapies.
Limitations: This report is based on transcriptomic analyses (bulk and single-cell) from existing trial datasets and organoid observations; it does not present prospective validation as a clinical diagnostic or an outcome measure.
This is a transcriptomic and organoid-focused analysis using existing clinical-trial datasets (bulk and single-cell). The finding is disease-specific to UC in these datasets and requires prospective validation before clinical use.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases, award R00DK136971
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
